Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms

Andrologia

Volumn 44, Issue SUPPL.1, 2012, Pages 791-795

  Ozturk M I ^a   Kalkan, S ^a   Koca, O ^a   Gunes M ^a   Akyuz M ^a   Karaman, M I ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Alpha blocker; Benign prostatic hyperplasia; Lower urinary tract symptoms; Sildenafil

Indexed keywords

ALFUZOSIN; SILDENAFIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MAXIMUM URINE FLOW RATE; MONOTHERAPY; ORGAN SIZE; POSTVOID RESIDUAL URINE VOLUME; PROSTATE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URINE FLOW RATE;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADULT; AGED; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSTATIC HYPERPLASIA; PURINES; QUINAZOLINES; SULFONES; URINATION DISORDERS;

EID: 84861509305     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/j.1439-0272.2011.01268.x     Document Type: Article

References (23)

1. Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, Rey H (2008) Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilotstudy. J Sex Med 5:2170-2178.
2. Carson CC (2006) Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 97(Suppl. 2):39-43.
3. Giuliano F, Kaplan SA, Cabanis MJ, Astruc B (2006) Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 67:1199-1204.
4. Kaplan SA, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717-1723.
5. Kedia GT, Uckert S, Kedia M, Kuczyk MA (2009) Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology 73:1397-1401.
6. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR, Pereira A (2004) Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 172:1935-1940.
7. Lee C, Kozlowski JM, Grayhack JT (1997) Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 31:131-138.
8. Leungwattanakij S, Watanachote D, Noppakulsatit P, Petchpaibuol T, Choeypunt N, Tongbai T, Wanamkang T, Lojanapiwat B, Permpongkosol S, Tantiwong A, Pripatnanont C, Akarasakul D, Kongwiwatanakul S, Chotikawanich E (2010) Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. J Sex Med 7:3115-3126.
9. MacDonald R, Wilt TJ (2005) Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology 66:780-788.
10. McNeill SA, Hargreave TB, Geffriaud-Ricouard C, Santoni J, Roehrborn CG (2001) Post-void residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. Urology 57:459-465.
11. McVary KT (2006) BPH: epidemiology and comorbidities. Am J Manag Care 12(5 Suppl.):122-128.
12. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177:1071-1077.
13. Mulhall JP, Guhring P, Parker M, Hopps C (2006) Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3:662-667.
14. Ponholzer A, Madersbacher S (2007) Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. Int J Impot Res 19:544-550.
15. Reynard JM (2004) Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol 14:13-16.
16. Roehrborn CG, Van Kerrebroeck P, Nordling J (2003) Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92:257-261.
17. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L (2010) Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 105:502-507.
18. Rosen R, Seftel A, Roehrborn CG (2007) Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. Int J Impot Res 19:480-485.
19. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC (2002) Sildenafil influences lower urinary tract symptoms. BJU Int 90:836-839.
20. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53:1236-1244.
21. Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A (2010) Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 28:17-22.
22. Uckert S, Küthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166:2484-2490.
23. Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M (2008) Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int 101:847-852.